PMID- 35844026
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20221122
IS  - 2095-0225 (Electronic)
IS  - 2095-0217 (Linking)
VI  - 16
IP  - 5
DP  - 2022 Oct
TI  - Anlotinib as third- or further-line therapy for short-term relapsed small-cell 
      lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202).
PG  - 766-772
LID - 10.1007/s11684-021-0916-8 [doi]
AB  - Patients with small-cell lung cancer (SCLC) relapse within months after 
      completing previous therapies. This study aimed to investigate the efficacy and 
      safety of anlotinib as third- or further-line therapy in patients with short-term 
      relapsed SCLC from ALTER1202. Patients with short-term relapsed SCLC (disease 
      progression within 3 months after completing ⩾ two lines of chemotherapy) in the 
      anlotinib (n = 67) and placebo (n = 34) groups were analyzed. The primary 
      endpoint was progression-free survival (PFS). The secondary endpoints included 
      overall survival, objective response rate (ORR), disease control rate, and 
      safety. Anlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P < 
      0.0001)/(7.3 vs. 4.4 months, P = 0.006) compared with placebo. The ORR was 
      4.5%/2.9% in the anlotinib/placebo group (P = 1.000). The DCR in the anlotinib 
      group was higher than that in the placebo group (73.1% vs. 11.8%, P < 0.001). The 
      most common adverse events (AEs) were hypertension (38.8%), loss of appetite 
      (28.4%), and fatigue (22.4%) in the anlotinib group and gammaglutamyl 
      transpeptidase elevation (20.6%) in the placebo group. No grade 5 AEs occurred. 
      For patients with short-term relapsed SCLC, third- or further-line anlotinib 
      treatment was associated with improved survival benefit. Further studies are 
      warranted in this regard.
CI  - (c) 2022. Higher Education Press.
FAU - Shi, Jianhua
AU  - Shi J
AD  - Department of Medical Oncology, Linyi Cancer Hospital, Linyi, 276002, China.
FAU - Cheng, Ying
AU  - Cheng Y
AD  - Department of Thoracic Medical Oncology, Jilin Cancer Hospital, Changchun, 
      130012, China. jl.cheng@163.com.
FAU - Wang, Qiming
AU  - Wang Q
AD  - Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, 450003, China.
FAU - Li, Kai
AU  - Li K
AD  - Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, 300060, China.
FAU - Wu, Lin
AU  - Wu L
AD  - Department of Thoracic Medical Oncology, The Affiliated Cancer Hospital of 
      Xiangya School of Medicine, Central South University (Hunan Cancer Hospital), 
      Changsha, 410031, China.
FAU - Han, Baohui
AU  - Han B
AD  - Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong 
      University, Shanghai, 200030, China.
FAU - Chen, Gongyan
AU  - Chen G
AD  - Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - He, Jianxing
AU  - He J
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou 
      Medical University, Guangzhou, 510120, China.
FAU - Wang, Jie
AU  - Wang J
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Beijing, 100021, China.
FAU - Qin, Haifeng
AU  - Qin H
AD  - Department of Pulmonary Oncology, The Fifth Medical Centre of Chinese PLA General 
      Hospital, Beijing, 100039, China.
FAU - Li, Xiaoling
AU  - Li X
AD  - Department of Medical Oncology, Liaoning Cancer Hospital, Shenyang, 110042, 
      China.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220716
PL  - China
TA  - Front Med
JT  - Frontiers of medicine
JID - 101549428
RN  - 0 (anlotinib)
RN  - 0 (Quinolines)
SB  - IM
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Treatment Outcome
MH  - Neoplasm Recurrence, Local/drug therapy/chemically induced
MH  - *Quinolines/adverse effects
OTO - NOTNLM
OT  - anlotinib
OT  - chemotherapy
OT  - short-term relapsed
OT  - small-cell lung cancer
EDAT- 2022/07/18 06:00
MHDA- 2022/11/23 06:00
CRDT- 2022/07/17 23:20
PHST- 2021/08/11 00:00 [received]
PHST- 2021/12/21 00:00 [accepted]
PHST- 2022/07/18 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/07/17 23:20 [entrez]
AID - 10.1007/s11684-021-0916-8 [pii]
AID - 10.1007/s11684-021-0916-8 [doi]
PST - ppublish
SO  - Front Med. 2022 Oct;16(5):766-772. doi: 10.1007/s11684-021-0916-8. Epub 2022 Jul 
      16.